Table 1. Demographics of the 44 patients with drug-induced interstitial lung disease (DIILD).
| Patient | Tumor | Drug | Smoking history/status | Preexisting ILD | Treatment for ILD | Study set |
|---|---|---|---|---|---|---|
| 1 | Lung | Gefitinib | Yes / current | No | DX + Oxygen | Screening |
| 2 | Lung | Gefitinib | Yes / former | Yes | PSL + Oxygen + CAZ | Screening |
| 3 | Lung | Erlotinib | No | Yes | MP + Oxygen + CFPM | Screening |
| 4 | Lung | Gefitinib | Yes / former | No | PSL + Oxygen + MEPM | Screening |
| 5 | Lung | Gefitinib | No | No | MP + Oxygen + MEPM + Warfarin | Screening |
| 6 | Lung | Gefitinib | Yes / former | Yes | PSL + Oxygen + CAZ | Screening |
| 7 | Lung | Erlotinib | Yes / former | Yes | DX | Screening |
| 8 | Lung | Gefitinib | Yes / former | No | PSL + Oxygen + BIPM | Screening |
| 9 | Lung | Gefitinib | No | No | MP + Oxygen + CAZ | Screening |
| 10 | Lung | Gefitinib | Yes / former | No | PSL + Oxygen + ST | Screening |
| 11 | Lung | Gefitinib | Yes / former | No | MP + Oxygen + PARM/BP | Screening |
| 12 | Lung | Gefitinib | Yes / former | Yes | PSL + Oxygen | Screening |
| 13 | Lung | Nivolumab | Yes | No | PSL + Oxygen | Screening |
| 14 | Lung | Nivolumab | Yes / former | No | MP + Oxygen + Carbocisteine + AZM + CAM | Screening |
| 15 | Lung | Nivolumab | Yes / former | No | Oxygen + Warfarin | Screening |
| 16 | Lung | Gefitinib | Unknown | Unknown | Unknown | Screening |
| 17 | Pancreas | Gemcitabine | Unknown | No | None | Screening |
| 18 | Pancreas | Gemcitabine | No | No | None | Screening |
| 19 | Pancreas | Gemcitabine | Yes | No | PSL + Ambroxol + ST + Cilostazol | Screening |
| 20 | Pancreas | Gemcitabinea | No | No | None | Screening |
| 21 | Pancreas | Gemcitabine + nab-PTX | No | No | PSL + CEZ | Screening |
| 22 | Pancreas | Gemcitabine + nab-PTX | No | No | PSL + Oxygen + TAZ/PIPC | Screening |
| 23 | Breast | Trastuzumab + paclitaxel | No | No | PSL + Oxygen + SBTPC + Warfarin | Screening |
| 24 | Breast | Trastuzumabb | No | No | ST | Screening |
| 25 | Breast | Trastuzumab + paclitaxel | No | No | None | Screening |
| 26 | Gastric | Trastuzumab + paclitaxel | Yes / former | No | PSL + Oxygen + ICS/LABA + ST | Screening |
| 27 | Lung | Nivolumab | Yes / unknown | No | PSL + CPFX | Replication |
| 28 | Lung | Nivolumab | Yes / unknown | No | PSL + ST | Replication |
| 29 | Lung | Nivolumab | Yes / former | No | PSL + ST | Replication |
| 30 | Lung | Nivolumab | Yes / unknown | No | PSL + Oxygen + ST | Replication |
| 31 | Lung | Nivolumab | Yes / former | No | PSL + ST | Replication |
| 32 | Lung | Nivolumab | Unknown | No | Eprazinone + AZM | Replication |
| 33 | Lung | Nivolumabc | Yes / unknown | No | MP + Oxygen + TAZ/PIPC + ST | Replication |
| 34 | Melanoma | Nivolumab | No | Yes | PSL + ST | Replication |
| 35 | Melanoma | Nivolumab | Yes / unknown | No | PSL | Replication |
| 36 | Melanoma | Nivolumab | No | No | PSL + Oxygen + ST | Replication |
| 37 | Melanoma | Nivolumab | Unknown | No | BMZ + Oxygen + ST | Replication |
| 38 | Melanoma | Nivolumab | No | Yes | PSL + ST | Replication |
| 39 | Breast | Trastuzumab + paclitaxel | No | No | PSL | Replication |
| 40 | Breast | Trastuzumab + paclitaxel | No | No | PSL | Replication |
| 41 | Breast | Trastuzumab + paclitaxel | No | No | PSL + CPFX | Replication |
| 42 | Breast | Trastuzumab + paclitaxel | No | No | PSL + Budesonide + ST | Replication |
| 43 | Gastric | Trastuzumabd | No | No | PSL + Oxygen + MEPM | Replication |
| 44 | Gastric | Trastuzumab emtansine | No | No | MP + Oxygen + TAZ/PIPC | Replication |
DX, Dexamethasone; PSL, Prednisolone; CAZ, Ceftazidime; MP, Methylprednisolone; CFPM, Cefepime; MEPM, Meropenem; BIPM, Biapenem; ST, Sulfamethoxazole trimethoprim; PARM/BP, Panipenem/betamipron; AZM, Azithromycin; CAM, Clarithromycin; CEZ, Cefazolin; TAZ/PIPC, Tazobactam/piperacillin; SBTPC, Sultamicillin; ICS/LABA, Inhaled corticosteroid/long-acting β-agonists; CPFX, Ciprofloxacin; BMZ, Betamethasone.
a This patient had DIILD during FOLFIRINOX (a combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) therapy following gemcitabine.
b This patient had DIILD during adriamycin + cyclophosphamide therapy following trastuzumab.
c This patient had DIILD during docetaxel therapy following nivolumab.
d This patient had DIILD during nanoparticle albumin-bound paclitaxel therapy following trastuzumab.